Compare Repligen Corporation Common Stock (RGEN) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs VICI Properties Inc — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while VICI Properties Inc trades at $23.16 (market cap $25.26B). The key difference: VICI Properties Inc is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and VICI Properties Inc pays a 8.02% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and VICI Properties Inc for 44 Days on average.
| RGEN | VICI | |
|---|---|---|
Market Cap | $11.31B | $25.26B |
Volume | 1,216,919 | 7,855,800 |
Sector | Health | Real Estate |
52-Week High | $194.57 | $31.42 |
52-Week Low | $102.87 | $22.53 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $11.20B | $42.81B |
Dividend Yield | — | 8.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a net income margin of 67.5% and a P/E ratio of 8.89, indicating potential undervaluation. Recent earnings showed a mix of beats and misses, while cash flow remains positive. The dividend was recently raised to $0.46 per share, payable in October 2026, reflecting income stability.
The outlook is supported by analyst consensus with a $28.90 price target and 75% buy ratings, but risks include tenant concentration and market overreaction to regional lease concerns. The stock offers value and income appeal, though investor sentiment is cautious due to recent price declines and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
